Warning: Undefined array key "network" in /hshare1/ZETTAI_path_WA_slash_usr_slash_proj_KARA/usr/proj/tcng/htdocs/tcng.php on line 565
Edge
PIM1 → SOCS3
Networks Including this Edge
| GSE18497_top8000 - GSE18497 - SiGN-BN NNSR | Diagnosis-relapse in ALL |
| GSE10245_egf1520 - GSE10245 - SiGN-BN HC+Bootstrap | Gene expression differences between adenocarcinoma and squamous cell carcinoma in human NSCLC |
| GSE12093_egf1520 - GSE12093 - SiGN-BN HC+Bootstrap | The 76-gene Signature Defines High-Risk Patients that Benefit from Adjuvant Tamoxifen Therapy |
| GSE18497_egf1520 - GSE18497 - SiGN-BN HC+Bootstrap | Diagnosis-relapse in ALL |
| GSE18728_egf1520 - GSE18728 - SiGN-BN HC+Bootstrap | Expression data from human breast cancers pre and post chemothrapy |
| GSE21653_egf1520 - GSE21653 - SiGN-BN HC+Bootstrap | A gene expression signature identifies two prognostic subgroups of basal breast cancer |
| GSE23177_egf1520 - GSE23177 - SiGN-BN HC+Bootstrap | Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs. |
| GSE23593_egf1520 - GSE23593 - SiGN-BN HC+Bootstrap | Intratumor Heterogeneity and Precision of Microarray-Based Predictors of Breast Cancer Biology and Clinical Outcome |
| GSE23772_egf1520 - GSE23772 - SiGN-BN HC+Bootstrap | Why does HAMLET preferentially kill tumor cells? p38-dependent death in tumor but up-regulation of innate immunity in healthy, differentiated cells |
| GSE26639_egf1520 - GSE26639 - SiGN-BN HC+Bootstrap | Expression Data from 226 patients of the REMAGUS02 trial |
| GSE27480_egf1520 - GSE27480 - SiGN-BN HC+Bootstrap | Gene-expression analysis of Oncostatin-M (OSM) signalling in cervical squamous cell carcinomas over-expressing the Oncostatin-M receptor (OSMR) |
| GSE5460_egf1520 - GSE5460 - SiGN-BN HC+Bootstrap | Predicting Features of Breast Cancer with Gene Expression Patterns |
| GSE6791_egf1520 - GSE6791 - SiGN-BN HC+Bootstrap | Gene Expression Profiles of HPV-Positive and -Negative Head/Neck and Cervical Cancers |
